. Author manuscript; available in PMC: 2016 Apr 25.

Published in final edited form as: Gynecol Oncol. 2010 Aug 16;119(2):270–273. doi: 10.1016/j.ygyno.2010.07.019

Table 3.

Analysis of recurrence-free survival

	N (%)	3-year RFS (95% CI)	P

Stage			0.093
II	15 (19)	91.7 (53.9–98.8)
III/IV	65 (81)	83.6 (70.8–91.1)

Micropapillary type			0.023
Yes	25 (31)	72.4 (48.3–86.6)
No	55 (69)	91.1 (78–96.6)

Invasive implants			0.005
Yes	19 (24)	66.7 (40.4–83.4)
No	61 (76)	93.6 (81.5–97.9)

Residual disease			N/A
Yes	8 (10)	71.4 (25.8–92)
No	69 (86)	89.4 (77.9–95.1)
Unknown	3 (4)

Adjuvant chemotherapy (all patients)			N/A
Yes	17 (21)	70.6 (43.1–86.6)
No	63 (79)	89.9 (77.3–95.7)

Adjuvant chemotherapy (patients without residual disease)			N/A
Yes	15 (22)	80 (50–93.1)
No	54 (78)	92.7 (79–97.6)